Study: Marchi 2025, BJPsych Open
The effect of Withania somnifera (Ashwagandha) on mental health symptoms in individuals with mental disorders: systematic review and meta-analysis
Citation
Marchi M, Grenzi P, Travascio A, Uberti D et al (2025). BJPsych Open. PubMed id 41140145.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Ashwagandha: cortisol, mood, skin, hair, heart, kidneys and liver Tier B thin
B 360 people treated and 353 controls in 14 randomised trials, people with mental disorders (mostly anxiety; inclusion was any age), median dose 600 mg a day, median follow-up 8 weeks (n=713)
Systematic review and meta-analysis, frequentist and Bayesian.
Ashwagandha improved anxiety, depression, stress and sleep quality compared with comparators. The Bayesian analysis confirmed the anxiety result but not the depression result. The authors list few studies, large differences between studies and outlier effects as limits. No significant difference in safety or tolerability.
As recorded in this card: Marchi M, Grenzi P, Travascio A, Uberti D et al (2025), BJPsych Open, [review]
Note: Depression finding is the weakest part. Ethnicity not reported in the abstract.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.